Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zuberitamab plus Pola-CHP for B-cell lymphoma-associated hemophagocytic lymphohistiocytosis
ChiCTR2600122617Phase 4Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Apr 2026
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of hlx01 in haemophagocytic lymphohistiocytosis (HLH) and mature B-cell lymphoma, sponsored by Ruijin Hospital. Primary endpoint: Complete Remission Rate. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
hlx01
03
Conditions
haemophagocytic lymphohistiocytosis (HLH)mature B-cell lymphoma
Beyond the preview
Go deeper on ChiCTR2600122617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600122617.